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Genotype-directed therapy holds great promise for the treatment of cancer, but crosstalk between
signaling pathways often confounds simple genotype-drug response relationships. To deliver on
the promise of precision medicine, a coordinated effort is needed to make a comprehensive
inventory of the many signaling feedback circuits that exist in cancer cells.Toward Genotype-Directed Cancer
Therapy
There is a trend in the treatment of cancer
from an approach in which the tissue of
origin and the histology were the guiding
principles for the choice of therapy
toward a strategy in which knowledge of
the oncogenic mutations is used to select
patients for treatment with highly selec-
tive drugs. This shift was enabled by
two major developments over the past
decades. First, the emergence of next-
generation DNA sequencing technologies
has enabled the identification of recurrent
mutations in a variety of cancers. Second,
the development of highly selective inhib-
itors of the products of genes that are
activated by these frequent genomic
alterations has provided medical oncolo-
gists with a new arsenal of more targeted
cancer therapeutics. Obviously, such
a radically new approach toward treat-
ment also requires a different method for
diagnosing cancer. In line with this, the
National Academy of Sciences has pub-
lished a report last year calling for a new
taxonomy of disease, based on molecular
rather than morphological parameters.
This should ultimately enable precision
medicine, in which subsets of patients
can be readily identified having a disease
of similar biological origin and who are
therefore most likely to benefit from
a specific drug treatment (Committee on
a Framework for Developing a New
Taxonomy of Disease, 2011). The benefits
of this new approach can be significant.
Current cancer treatments are highly inef-
ficient, delivering benefit on average to
only 25% of the patients (Spear et al.,2001). Also, in economic terms, the
conventional approach is unsustainable.
Global annual spending on cancer drugs
was around $49 billion in 2011, of which,
by inference, some $ 37 billion was spent
to cause adverse side effects without
delivering patient benefit.
TheCancerGenotype as aPredictor
of Response to Therapy
Genotype-directed precision medicine
holds the promise to greatly improve
cancer survival by delivering the most
effective drugs to the right patients.
Indeed, great progress has been made
in treatment of diseases like chronic
myelogenous leukemia (CML). Current
precision treatment strategies targeting
the product of the BCR-ABL oncogene
with targeted agents like imatinib have
more than doubled 5-year survival rates
of CML to >95%, a number that is similar
to what is seen in the general population.
This strong relationship between the
BCR-ABL genotype and the response
to the ABL kinase inhibitor imatinib is
most readily explained by what the late
Bernhard Weinstein dubbed ‘‘oncogene
addiction,’’ an acquired dependence
of the cancer on the ‘‘driver’’ mutation
that fuels oncogenic growth (Weinstein,
2002). This and other initial successes in
targeting the oncogenic drivers of cancer
have spurred globally coordinated efforts
to genotype thousands of cancers. Such
studies have already yielded a wealth of
new information on recurrent genomic
alterations in diverse cancer types. A
complicating factor in using genomic
information to select patients for therapyCell 151is that some cancers contain many muta-
tions, making such tumors potentially less
dependent on a single oncogenic event.
Nevertheless, even today, clinicians
already use the presence of a number of
these genomic changes in cancer as
a diagnostic tool to select patients for
treatment with targeted agents. It should
be pointed out, however, that in spite of
the avalanche of publications on targeted
cancer therapies of recent years, the vast
majority of cancer patients are still treated
with conventional chemotherapies, the
clinical benefit of which is virtually impos-
sible to predict for the individual patient.
Crosstalk between Signaling
Pathways
Virtually all of the clinically relevant
changes in cancer genomes are based
on the principle that one mutation is
selected for treatment with a matching
drug. A complication in this simple
scenario is that many of the cellular
signaling pathways are interconnected
to maintain homeostasis. For instance,
inhibition of the mTORC1 complex with
rapamycin-like drugs causes activation
of phosphatidylinositol 3-kinase (PI3-
kinase) and AKT, dampening a response
to single-agent mTORC1 inhibitors. Simi-
larly, inhibition of AKT leads to activation
of multiple receptor tyrosine kinases
(RTKs), which attenuate the effect of AKT
inhibition (Chandarlapaty et al., 2011).
Moreover, inhibition ofMEK in triple-nega-
tive breast cancer also causes activation
of RTKs, precluding a response to single-
agent MEK inhibition in vivo (Duncan
et al., 2012). These examples illustrate, October 26, 2012 ª2012 Elsevier Inc. 465
Figure 1. Feedback Circuits between Signaling Pathways
(A) Feedback circuits often display synthetic lethal interactions. Inhibition of a single activated component
(in orange) of a major signal transduction pathway can lead to feedback activation of another signaling
pathway, which supports cell viability while the oncogenic driver is inhibited (center). Only combined
inhibition of both the oncogenic driver and the target of the feedback circuit leads to cell death (right).
(B) Genetic screens to identify synthetic lethal interactions. Cancer cells are infected with collections of
retroviral shRNA vectors. Infected cells are divided into two duplicate populations, of which one is treated
with a drug that targets a cancer-specific oncogenic lesion. The cancer cell only dies when a critical
component of the feedback circuit is inactivated by shRNA, leading to depletion of that specific shRNA
from the population. Drug-depleted shRNA vectors can be identified through deep sequencing of bar code
identifiers that are present in each shRNA vector.the dynamic interactions between the
major signaling pathways in cancer. At
the same time, they emphasize that tar-
geting a single activated pathway in
cancer may not yield the desired thera-
peutic benefit due to feedback activation466 Cell 151, October 26, 2012 ª2012 Elseviof pathways that circumvent the road-
block imposed by the cancer drug.
A particularly striking example of this is
the case of BRAF mutant cancers. In
agreement with the oncogene addiction
model, patients withBRAF(V600E)mutanter Inc.melanoma respond very well to a small-
molecule inhibitor of the BRAF kinase
(Chapman et al., 2011). However, to the
surprise of many, Kopetz and colleagues
found that BRAF(V600E) mutant colon
tumors were almost invariably resistant
to the very same BRAF inhibitor that had
proven to be so successful in treating
melanomaswith the identicalBRAFmuta-
tion (S. Kopetz et al., 2010, Am. Soc. Clin.
Oncol., abstract). The resolution for this
apparent disparity came recently, when
it was found that BRAF mutant colon
cancers activate the epidermal growth
factor receptor (EGFR) through a feed-
back mechanism upon inhibition of the
BRAF kinase, which fuels proliferation in
the presence of BRAF inhibition (Prahal-
lad et al., 2012). In contrast to colon
cancer, EGFR is normally not expressed
in melanoma, explaining the absence of
intrinsic BRAF inhibitor resistance in
melanoma. This example, in which tumor
types having the very same BRAF muta-
tion respond radically differently to BRAF
inhibition, further highlights the discon-
nect that can exist between the geno-
types of cancers and their predicted
drug responses.
Functional Genetic Screens as
a Tool to Map Feedback Circuits
A potential way to deal with these feed-
back mechanisms in the clinic is to target
not only the activated oncoprotein itself,
but also the pathway activated by the
feedback mechanism that resulted from
inhibition of the primary target. Indeed,
in colon cancer cells, simultaneous inhibi-
tion of both BRAF and EGFR causes
responses far beyond what can be
achieved with each drug alone (Corcoran
et al., 2012; Prahallad et al., 2012). This
interaction between BRAF and EGFR is
referred to in genetic terms as a ‘‘synthetic
lethal’’ interaction; a situation in which
inhibition of each gene product alone
yields no effect, but simultaneous inhibi-
tion of both is lethal to the cell. Feedback
circuits are particularly likely to display
synthetic lethal interactions, as the very
nature of the feedback loop is often to
dampen the effects of pathway inhibition
(Figure 1A).
Unbiased discovery of synthetic lethal
interactions between signaling pathways
in cancer is enabled by loss-of-function
genetic screens using RNA interference
(Kaelin, 2005). When inhibition of an acti-
vated oncogene alone elicits no thera-
peutic benefit, one can identify the redun-
dant signaling pathway that allows cancer
cell survival in the presence of drug
through functional genetics. By system-
atic inactivation of all major nodes in
signaling pathways, one can ask which
other pathway needs to be inhibited
to make the ineffective cancer drug
effective in combination (Figure 1B).
There are two important aspects to this
particular synthetic lethality approach.
First, the drug that targets the activated
oncogene is, in principle, cancer selec-
tive, as only the cancer cells harbor the
activated oncogene. This should, at least
in theory, limit toxicity to normal tissues.
Second, the gene that displays a synthetic
lethal interaction with the cancer-specific
mutation may not be a recurrently
mutated gene in cancer itself and hence
may not be a target for oncology drug
discovery today. Thus, a systematic
search for synthetic lethal interactions in
cancer may yield a wealth of new drug-
gable targets (kinases are often the
nodes of signaling pathways) that are
not active when used as single agent but
become very potent when combined
with their synthetic lethal drug partner.
The use of synthetic lethal drug combina-
tions may also circumvent drug resis-
tance, an almost inevitable problem in
patients with advanced cancer treated
with single agents. A lesson learned from
the treatment of HIV (also genetically
unstable, like many human cancers) is
that escape from combination therapies
is much less likely. Targeting cancers
with pairs of highly effective synthetic
lethal drugs may therefore also reduce
the emergence of drug-resistant variants
and hence prolong progression free
survival.
Combinations of Targeted Cancer
Therapies: Roadblocks to
Implementation
In spite of the logic of using combinations
of targeted cancer agents, the road to
clinical success of this approach is likely
to be bumpy. A first issue is whether cell
line models of cancer are suitable to
predict which combination therapies are
likely to be effective in the clinic. In the
past, cell line models have not been very
helpful to identify biomarkers of responseto chemotherapy. However, there is
reason to be more optimistic about
their utility for predicting responses to
(combinations of) targeted therapies.
Connections between signaling path-
ways are often hard-wired in the cell and
consequently less dependent on the
microenvironment. Nevertheless, it will
be important to investigate the utility of
other cancer models for predicting drug
responses, such as three-dimensional
cell culture systems and patient-derived
mouse xenograft models of cancer. A
second issue that will complicate the
use of combinations of targeted therapies
is that these drugs too have side effects.
This will limit the number of two- and
three-way drug combinations that are
practically feasible in the clinic while
maintaining proper suppression of the
intended drug targets. Finally, it is likely
that functional genetic screens as out-
lined above will more often than not
identify combinations of drugs that are
being developed by different pharmaceu-
tical or biotechnology companies. Testing
such combinations will require a new
model for cooperation between such
companies. Fortunately, we have seen
the first signs that such partnerships are
indeed possible. In 2009, Merck and
AstraZeneca agreed to conduct a joint
phase 1 clinical trial combining AstraZe-
neca’s MEK inhibitor with Merck’s AKT
inhibitor. Such partnerships are likely to
become more common as we learn how
we need to combine targeted therapies
to maximize therapeutic responses.
A Call for a Coordinated Search
for Synthetic Lethal Interactions
in Cancer
The identification of synthetic lethal drug
combinations as depicted in Figure 1B
holds great promise for future develop-
ment of effective combination therapies,
but it also represents a huge logistical
hurdle to accomplish. Whereas cancer
genome sequencing projects are highly
coordinated globally, functional genetic
screens are performed by individual labo-
ratories without any coordination. Yet, the
amount of work to make a complete
inventory of all crosstalk circuits between
the major signaling pathways is far too
large for any single laboratory to handle.
As one example, BRAF and KRAS muta-
tion are mutually exclusive in colonCell 151cancer, consistent with the notion that
they both act in the RAF-RAS-MEK-
signaling pathway. However, inhibition
of BRAF elicits different feedback
responses in BRAF mutant colon tumors
than inhibition of the downstream MEK
kinase in KRAS mutant colon cancer.
We will therefore have to make an inven-
tory of all signaling network interactions
for all cancer genotypes in each tissue
type to identify the most effective drug
combinations. In spite of the significant
efforts that are ongoing at individual labo-
ratories (e.g., www.broadinstitute.org/
software/cprg/?q=node/10), a compre-
hensive inventory of all synthetic lethal
interactions in cancer will require a glob-
ally coordinated effort, not unlike the
coordination between the large genome
centers that work together to sequence
thousands of cancer genomes. How-
ever, coordination of functional genetic
screens may represent a larger logistical
hurdle in that there are no standardized
reagents and no agreed standard oper-
ating procedures to perform such screens
between laboratories. This lack of stan-
dardization makes it impossible at
present to compare results between indi-
vidual laboratories. If two laboratories
perform a synthetic lethal screen and
the results differ, it is impossible to
know whether the differences in outcome
are due to technical differences or
true biological differences between the
two systems. The adage ‘‘absence of
evidence is no evidence for absence,’’
is most certainly applicable to RNAi
screens. A gene may not show up in
a genetic screen for any number of trivial
technical reasons, but it can also be bio-
logically significant that it did not show
up. Only if we agree on a common set of
reagents and standardized protocols to
perform such screens will we be able to
compare results between laboratories in
a meaningful way.
Today, there is almost universal convic-
tion that cancer genome sequencing
will deliver the ingredients to select
patients for individualized therapy. I argue
here that, in addition, an inventory of feed-
back and crosstalk circuits between
signaling pathways will be instrumental
in finding the right drug combinations for
each individual patient. Our lack of under-
standing of the way in which signal-
ing networks interconnect represents a, October 26, 2012 ª2012 Elsevier Inc. 467
critical missing link in realizing the ultimate
goal of personalized medicine. The tech-
nology to identify these connections is
available, and initial proof of concept
has been delivered, making the entire
project feasible. What seems to be
missing is a concerted funding effort
and a consortium of laboratories to
make this happen. It may be that this
qualifies as a ‘‘neglected area of
oncology’’ that the National Cancer
Institute is targeting for funding through
the provocative questions initiative
(http://provocativequestions.nci.nih.gov).
Cancer patients have much to gain from
effective combination therapies based
on insights into how the major signaling
pathways communicate within their
cancer cells.468 Cell 151, October 26, 2012 ª2012 ElseviACKNOWLEDGMENTS
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